Loading resource…

Janneke Ravensberg, MD; Jacobijn Gussekloo, MD, PhD; Saskia Le Cessie, PhD; Olaf M. Dekkers, MD, PhD; Simon P. Mooijaart, MD, PhD; Rosalinde K. E. Poortvliet, MD, PhD
The research is a single-group, prospective study involving community-dwelling adults aged 60 years or older who had been on a stable dosage of levothyroxine for at least one year. The study was conducted across 58 general practices in the Netherlands, enrolling participants from January 2020 to July 2022, with follow-up concluding in December 2023. The primary outcome measured was the proportion of participants who could discontinue levothyroxine while maintaining normal thyroid function.
No account needed